2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
12:00 p.m. - 01:30 p.m.
MCCNO - 220-222
Transfusion medicine is rapidly evolving from the delivery of standardized blood products toward precision, data-driven therapies tailored to individual patients and clinical contexts. This session highlights cutting-edge advances spanning the continuum of transfusion care. Topics range from optimizing stem cell mobilization and red cell exchange in patients with sickle cell disease, to reducing alloimmunization through precision antigen matching, improving hemostatic management in cardiac surgery, uncovering the biological effects of platelet transfusions on the developing brain, and developing next-generation recombinant oxygen-carrying blood substitutes. Together, these presentations demonstrate how innovations in transfusion science are improving the safety, effectiveness, and sustainability of blood therapies while laying the foundation for future alternatives to donor-derived blood.
Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Gene Therapy, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemoglobinopathies, Sickle Cell Disease, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

162 Time course of adjunctive hemostatic therapies and transfusions in FARES-II: Post hoc analysis of a randomized trial of prothrombin complex concentrate versus frozen plasma for coagulopathic bleeding in cardiac surgery

Keyvan Karkouti, MD, Jeannie Callum, MD, FRCPC2, Justyna Bartoszko3, Michelle Zeller, MD, MSc, FRCPC4, Yulia Lin, MD5, Darren Mullane6, Cristina Solomon, MD, MBA7, Sigurd Knaub, PhD8, Sylvia Werner, MSc9, Kenichi A Tanaka10, Jerrold H Levy, MD11
1 University Health Network, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
2 Kingston Health Sciences Centre, Kingston, Ontario, Canada, Queen's University, Kingston, Ontario, Canada
3 University Health Network, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
4 Canadian Blood Services, Ottawa, Ontario, Canada, McMaster University, Hamilton, Ontario, Canada
5 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
6 University of British Columbia, Vancouver, British Columbia, Canada, Vancouver General Hospital, Vancouver, British Columbia, Canada
7 Octapharma AG, Lachen, Switzerland
8 Octapharma AG, Lachen, Switzerland
9 Octapharma USA, Inc., Paramus, New Jersey, United States
10 University of Oklahoma-Health Sciences Center, Oklahoma City, Oklahoma, United States
11 Duke University School of Medicine, Durham, North Carolina, United States, University of British Columbia, Vancouver, British Columbia, Canada

Introduction:

The FARES-II study demonstrated superior hemostatic efficacy of 4-factor prothrombin complex concentrate (4F-PCC; Octaplex/BALFAXAR, Octapharma) vs frozen plasma (FP) for coagulopathic bleeding post cardiopulmonary bypass (CPB) in cardiac surgery patients (currently off-label in the US), supported by the primary and multiple secondary efficacy endpoints [JAMA 2025;333:1781–92]. The rate of thromboembolic events was similar between the treatment groups, while serious adverse events and acute kidney injury rates were significantly lower with 4F-PCC. This post-hoc analysis describes the use of additional hemostatic therapies before and after study drug, providing a comprehensive assessment of coagulation management during the study.

Methods:

FARES-II (LEX-211; NCT05523297) included patients ≥18 years undergoing cardiac surgery with CPB at 12 sites in Canada and the US. After protamine, bleeding patients with INR ≥1.5 were randomized 1:1 to 4F-PCC (1500 IU if ≤60 kg; 2000 IU if >60 kg) or FP (3 U if ≤60 kg; 4 U if >60 kg) as investigational medicinal product (IMP). Clinical teams were blinded to group allocation until treatment start.

The primary endpoint was hemostatic response (effective if no additional hemostatic interventions were administered from 60 min to 24 h after IMP start). Since bleeding after CPB is highly dynamic and multifactorial, with low thrombin generation as only one component, a pragmatic design was used whereby other hemostatic agents and allogeneic blood products besides IMP were given according to local standard-of-care practice to manage fibrinogen deficiency, thrombocytopenia, and anemia. Secondary endpoints included the use of non-IMP coagulation factor concentrates such as fibrinogen concentrate (FC) and the incidence of transfusion of platelets, red blood cells (RBC), and non-IMP FP. This post hoc analysis evaluated the use of these treatments in the post-CPB period before IMP and through 24 h after IMP start.

Results:

Of 538 enrolled patients, 420 were randomized, treated, consented, and included in the analysis (4F-PCC=213; FP=207). Baseline characteristics were comparable between groups. The primary endpoint was achieved in 77.9% (n=166) of 4F-PCC vs 60.4% (n=125) of FP patients (p<0.0001 for superiority).

From CPB end to just prior to IMP start, use of key blood products and hemostatic agents was comparable between the treatment arms. FC was administered in 47 (22.1%) 4F-PCC and 52 (25.1%) FP patients, platelets in 93 (43.7%) 4F-PCC and 95 (45.9%) FP patients, and RBCs in 30 (14.1%) 4F-PCC and 28 (13.5%) FP patients. Use of FP pre IMP was minimal, occurring in 2 (0.9%) patients in the 4F-PCC group and 0 patients in the FP group.

In the first 60 min after IMP start, use of FC (36 [16.9%] vs 31 [15.0%]), recombinant activated factor VII (rFVIIa; 2 [0.9%] vs 2 [1.0%]), platelets (75 [35.2%] vs 78 [37.7%]), RBCs (45 [21.1%] vs 59 [28.5%]), and FP other than IMP (1 [0.5%] in both groups) was comparable between the 4F-PCC and FP groups.

From 60 min to 24 h post IMP start, more patients in the FP vs 4F-PCC group received FC (23 [11.1%] vs 14 [6.6%]; p=0.11), rFVIIa (9 [4.3%] vs 0; p=0.04), platelets (63 [30.4%] vs 32 [15.0%]; p<0.001), and RBCs (132 [63.8%] vs 97 [45.5%], within 24 h post IMP start; p<0.001); non-IMP FP was transfused in 7 (~3.3%) patients in each group (p=0.96).

The number of patients who received a second IMP dose in the first hour after initial IMP start was higher in the 4F-PCC (18 [8.5%]) vs FP group (7 [3.4%]). However, more patients in the FP group received a second IMP dose in the second hour after initial IMP start (20 [9.7%] vs 5 [2.3%]). When a second IMP dose was not counted as treatment failure, 4F-PCC still demonstrated superior hemostatic efficacy vs FP: 80.8% vs 62.3%, p<0.0001.

Conclusions:

In FARES-II, the treatment groups were well balanced with respect to use of additional hemostatic treatments before and after randomization to 4F-PCC or FP, demonstrating comparable management of fibrinogen deficiency, thrombocytopenia, and anemia. However, from 1–24 h after study drug initiation, use of adjunctive hemostatic treatments was higher in the FP group. This finding may reflect the larger transfusion volumes of FP contributing to hemodilution and less effective bleeding control, necessitating additional hemostatic therapy. These results further support the superior hemostatic efficacy of 4F-PCC compared to FP for bleeding management in cardiac surgical patients.

Cristina Solomon, MD, MBA: Octapharma - Current Employment